GLP-1 (1-37) (human, bovine, guinea pig, mouse, rat) trifluoroacetate salt

Modify Date: 2024-01-02 13:04:10

GLP-1 (1-37) (human, bovine, guinea pig, mouse, rat) trifluoroacetate salt structure	Common Name	GLP-1 (1-37) (human, bovine, guinea pig, mouse, rat) trifluoroacetate salt
	CAS Number	87805-34-3	Molecular Weight	4169.48
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₁₈₆H₂₇₅N₅₁O₅₉	Melting Point	N/A
	MSDS	USA	Flash Point	N/A

Use of GLP-1 (1-37) (human, bovine, guinea pig, mouse, rat) trifluoroacetate salt

Glucagon-like peptide 1 (1-37), human is a highly potent agonist of the GLP-1 receptor.

Name	GLP-1 (1-37) amide
Synonym	More Synonyms

Description	Glucagon-like peptide 1 (1-37), human is a highly potent agonist of the GLP-1 receptor.
Related Catalog	Signaling Pathways >> GPCR/G Protein >> Glucagon Receptor Peptides Research Areas >> Metabolic Disease
Target	GLP-1 receptor[1]
In Vitro	Glucagon-like peptide-1 (GLP-1) is produced by the posttranslational processing of proglucagon and acts as a regulator of various homeostatic events. GLP-1(1-37) is more stable than GLP-1(7-37), with 94.7% of the initial amount of peptide left after a 4h exposure to mouse serum. GLP-1(1-37) is confirmed to be a highly potent agonist of the GLP-1 receptor (GLP-1R) by measuring the expression of the luciferase reporter gene expression in transiently transfected human embryonic kidney (HEK293) cells[1].
In Vivo	GLP-1(1–37) decreased glycemic excursion in a dose-dependent. The administration of GLP-1(1–37) or GLP-1(7–37) markedly decrease blood glucose levels at 15 min and 30 min compared with the control group[1].
Cell Assay	HEK293 cells (5×104) are seeded in a 96-well plate and transiently cotransfected with the GLP-1R plasmid and the CRE-luciferase reporter plasmid. After a 48 h transfection, different concentrations of GLP-1(1–37) or GLP-1(7–37) are added, and the cells are incubated for 5 h. The cells are harvested for a luciferase assay using a luciferase assay[1].
Animal Admin	Mice[1] The normal KM mice are fasted for 16 h before the administration (i.p.) of GLP-1 and glucose. GLP-1(1-37) (25 nmol/kg) with or without exendin(9-39) (250 nmol/kg) is given in combination with glucose (4 g/kg). GLP-1(7-37) (25 nmol/kg) with or without exendin(9-39) (250 nmol/kg) is also administrated in combination with glucose (4 g/kg). The control group is treated with saline (NaCl, 9 g/l) and glucose (4 g/kg). The IPGTT is carried out at 0, 15, 30 and 60 min after glucose and protein administration, and the blood glucose levels are measured as described above[1].
References	[1]. Zhao L, et al. Glucagon-like peptide-1(1-37) can enhance blood glucose homeostasis in mice. Regul Pept. 2012 Oct 10;178(1-3):1-5.

Molecular Formula	C₁₈₆H₂₇₅N₅₁O₅₉
Molecular Weight	4169.48
Storage condition	−20°C

Personal Protective Equipment	Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter
RIDADR	NONH for all modes of transport
WGK Germany	3

GLP-1-related proteins attenuate the effects of mitochondrial membrane damage in pancreatic β cells.

Biochem. Biophys. Res. Commun. 447(1) , 133-8, (2014)

Glucagon-like peptide (GLP)-1 analog based therapies are used not only for their insulinotropic effects, but also for their pleiotropic effects that improve pancreatic β cell function. Liraglutide is ...

Glucagon-like peptide-1 and blood pressure in young and healthy adults from the general population.

Hypertension 65(2) , 306-12, (2015)

Hypertension and diabetes mellitus are highly correlated, but the underlying mechanisms are only partly understood. Therefore, the aim of our study was to investigate the relationships between plasma ...

The low level of glucagon-like peptide-1 (glp-1) is a risk factor of type 2 diabetes mellitus.

BMC Res. Notes 7 , 849, (2014)

Glucagon like peptide-1 (GLP-1), an incretin hormone, regulates glucose metabolism by inducing insulin secretion and suppressing glucagon secretion. The aim of the study is to assess the levels of fas...

Glucagon-like peptide 1 (1-37)

Glucagon-like peptide 1 (1-37) (human, rat)

Glucagon-like peptide 1 (1-37), human